Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 10/20 | 0.73 |
| ▸ | MEN1 | O00255 | 9/20 | 0.73 |
| ▸ | MAPT | P10636 | 7/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.65 |
| ▸ | GSK3A | P49840 | 4/20 | 0.59 |
| ▸ | GSK3B | P49841 | 4/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.58 |
| ▸ | POLB | P06746 | 3/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.58 |
| ▸ | RECQL | P46063 | 2/20 | 0.58 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.58 |
| ▸ | MMP2 | P08253 | 1/20 | 0.58 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.58 |
| ▸ | APEX1 | P27695 | 1/20 | 0.58 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.58 |
| ▸ | HBB | P68871 | 1/20 | 0.58 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
| ▸ | BLM | P54132 | 2/20 | 0.53 |
| ▸ | USP2 | O75604 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17717942 | 0.88 | KMT2A (0.59) | KMT2AMEN1MAPTALDH1A1GSK3A | |
| SCHEMBL21359663 | 0.85 | KMT2A (1.00) | KMT2AMEN1MAPTALDH1A1GSK3A | |
| SCHEMBL30998816 | 0.83 | ALDH1A1 (0.72) | KMT2AMEN1MAPTALDH1A1HSD17B10 | |
| SCHEMBL209877 | 0.83 | ALDH1A1 (0.72) | KMT2AMEN1MAPTALDH1A1GSK3A | |
| SCHEMBL7734082 | 0.83 | MEN1 (0.66) | KMT2AMEN1MAPTALDH1A1GSK3A | |
| SCHEMBL13729308 | 0.82 | KMT2A (0.64) | KMT2AMEN1MAPTALDH1A1GSK3A | |
| Potassium SCHEMBL11515942 | 0.81 | ALDH1A1 (0.70) | KMT2AMEN1MAPTALDH1A1GSK3A | |
| SCHEMBL1495220 | 0.81 | MEN1 (0.52) | KMT2AMEN1MAPTALDH1A1HSD17B10 | |
| SCHEMBL18835712 | 0.80 | MEN1 (0.67) | KMT2AMEN1MAPTALDH1A1GSK3A | |
| SCHEMBL15419594 | 0.79 | KMT2A (0.65) | KMT2AMEN1MAPTALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1107 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118064087-A | Precipitate-free single-component epoxy adhesive and preparation method and application thereof | 深圳市汉思新材料科技有限公司 | 2024-05-24 | — | — | CN | claimed |
| WO-2021054927-A2 | GLUTATHIONE-CHOLESTEROL DERIVATIVES AS BRAIN TARGETING AGENTS | SOUTH DAKOTA BOARD OF REGENTS (US) | 2021-03-25 | — | — | WO | claimed |
| US-20200048305-A1 | GLUTATHIONE-CHOLESTEROL DERIVATIVES AS BRAIN TARGETING AGENTS | SOUTH DAKOTA BOARD OF REGENTS (US) | 2020-02-13 | — | — | US | claimed |
| US-9770514-B2 | Tamper-resistant pharmaceutical dosage forms | ExxPharma Therapeutics LLC (US) | 2017-09-26 | — | — | US | claimed |
| US-9622969-B2 | Polymer conjugated protein micelles | SOUTH DAKOTA STATE UNIV (US) | 2017-04-18 | — | — | US | claimed |
| US-20150064250-A1 | Tamper-Resistant Pharmaceutical Dosage Forms | ExxPharma Therapeutics LLC (US) | 2015-03-05 | — | — | US | claimed |
| US-20140370110-A1 | POLYMER CONJUGATED PROTEIN MICELLES | SOUTH DAKOTA STATE UNIVERSITY (US) | 2014-12-18 | — | — | US | claimed |
| CN-101415328-B | Methods and compositions for ameliorating or inhibiting decline in memory or intelligence or improving same | MASSACHUSETTS INST TECHNOLOGY | 2014-03-05 | — | — | CN | claimed |
| CN-103599124-A | Compositions containing CDP-choline, and methods of use thereof | MASSACHUSETTS INST TECHNOLOGY | 2014-02-26 | — | — | CN | claimed |
| EP-2560634-A1 | NITRIC OXIDE RELEASING PRODRUGS OF THERAPEUTIC AGENTS | Piramal Enterprises Limited (IN) | 2013-02-27 | — | — | EP | claimed |
| US-20070043120-A1 | Therapeutic combination for painful medical conditions | UCB PHARMA GMBH (DE) | 2007-02-22 | — | — | US | claimed |
| US-20070042969-A1 | Combination therapy for pain in painful diabetic neuropathy | SRZ PROPERTIES, INC. (US) | 2007-02-22 | — | — | US | claimed |
| US-20060135551-A1 | Novel heterocyclic compounds and their pharmaceutical compositions | DR. REDDY'S LABORATORIES LTD. (IN) | 2006-06-22 | — | — | US | claimed |
| JP-2003517437-A | — | — | 2003-05-27 | — | — | JP | claimed |
| US-20020028787-A1 | Nervous system disorders; administering exogenous uridine compound | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2002-03-07 | — | — | US | claimed |
| EP-1140104-A1 | METHODS FOR INCREASING CYTIDINE LEVELS IN VIVO AND TREATING CYTIDINE-DEPENDENT HUMAN DISEASES | Massachusetts Institute of Technology (US) | 2001-10-10 | — | — | EP | claimed |
| CN-1294519-A | Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient | INPHARMA SA (CH) | 2001-05-09 | — | — | CN | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
| US-3995021-A | DIAZOTIZATION OF AN AMINO PHENYL SUBSTITUTED HAPTEN | BIOLOGICAL DEVELOPMENTS, INC. (US) | 1976-11-30 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070042969-A1 | Combination therapy for pain in painful diabetic neuropathy | GRIN2B, GRIN2A, GRIN3A | KMT2A 617/4885MEN1 4370/4885MAPT 1158/4885 |
| US-20200048305-A1 | GLUTATHIONE-CHOLESTEROL DERIVATIVES AS BRAIN TARGETING AGENTS | GSTK1, GSTO1, GSTM2 | KMT2A 3630/4885MEN1 1607/4885MAPT 1050/4885 |
| US-20140370110-A1 | POLYMER CONJUGATED PROTEIN MICELLES | MTDH, PSMG3, GHITM | KMT2A 3102/4885MEN1 906/4885MAPT 651/4885 |
| US-20070043120-A1 | Therapeutic combination for painful medical conditions | PDE1B, CA2, CACNA1S | KMT2A 1606/4885MEN1 1264/4885MAPT 1343/4885 |
| US-20060135551-A1 | Novel heterocyclic compounds and their pharmaceutical compositions | LIPC, PCSK9, PC | KMT2A 3247/4885MEN1 1019/4885MAPT 2438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.